与此同时，公司全球化布局正从单纯的硬件输出向解决方案输出升级。在意大利，公司为费拉拉医院定制U-blood智能血 液管理系统，让中国智慧用血方案提升医院管理效能与安全性，减少血液浪费；在英国，公司为玛丽女王大学在24小时内提供 定制化的实验室服务方案，成功容纳64台生物安全柜，以高效可靠的交付能力赢得客户信赖。 这些成果得益于公司深化"一国一策"本土化战略，在地化运营团队已覆盖英国、新加坡、阿联酋、法国等18个国家，当地 化产品认证达400余项。值得关注的是，由于在地化运营团队投入增加，公司在提高运营效率的同时也带来成本阶段性上升， 但这也为全球化服务的响应速度和交付质量提供了坚实保障。 营收占比突破36% 深耕生命科学领域上游的企业，海尔生物海外市场持续增长，2016年至2024年海外收入复合增长率超过20%。2025年， 2025年公司实现海外收入8.4亿元，同比增长17.9%，占公司主营收入比重再创新高达到36%，较2024年提升5个百分点。其中欧 洲区域表现尤为突出，该区域收入同比增长16.0%，亚太区域收入同比增长26.0%，美洲区域收入同比增长12.2%，非洲区域收 入同比增长17.8%。 凭借高 ...

Core Viewpoint - The company, Zhongke Meiling Cryogenic Technology Co., Ltd., is utilizing idle funds for cash management, with a maximum investment of 260 million RMB in bank financial products while ensuring operational liquidity and risk control [1] Group 1: Financial Management - The company announced the use of 110 million RMB of idle self-owned funds for cash management, with a remaining balance of 230 million RMB in self-owned financial products [1] - The maximum amount for investment in bank financial products is set at 260 million RMB [1] Group 2: Company Overview - Zhongke Meiling was established in 2002 in Hefei, Anhui Province, and is one of the early entrants in the biological cell ultra-low temperature storage sector [1] - The company specializes in the research, production, and sales of a wide range of low-temperature storage equipment and provides comprehensive solutions in the biomedical field [1] Group 3: Achievements and Recognition - The company is recognized as a high-tech enterprise and a national-level "specialized and innovative" small giant enterprise, receiving numerous awards including the National Technology Invention Award (second prize) and various provincial and municipal honors [2] - The company aims to enhance its core refrigeration technology in the biomedical field and accelerate domestic substitution efforts [2] Group 4: Performance Metrics - In the first three quarters of 2025, the company achieved operating revenue of 224 million RMB, representing a year-on-year growth of 4.75%, and a net profit attributable to shareholders of 12.76 million RMB, with an increase of 8.19% year-on-year [3]

Group 1 - Hainan Free Trade Port is set to enter a new phase of development in 2026, with various industries seizing new policy opportunities post-closure [1] - Hainan has selected over a hundred quality projects from its "14th Five-Year Plan" for development, covering all 18 cities and counties, including low-altitude economy and tropical agriculture [3] - A business leader indicated that with sufficient funding, they expect to generate 200 to 300 million yuan in equipment output by 2026, expressing confidence in establishing and growing their operations in Hainan [6] Group 2 - Hainan has seen a significant increase in tourist numbers, with inbound visitors to Sanya and Haikou rising by 28% and 15% respectively during the first week of the new year [10] - The duty-free shopping in Hainan has surged, with sales amounting to 1.21 billion yuan in the first week of the new year, marking an 88% year-on-year increase, and nearly 150,000 shoppers, a 38.3% increase [15] - The marketing director of a global duty-free city reported a 10% increase in inventory for new product categories, anticipating a busy shopping season as the Spring Festival approaches [21] Group 3 - Since the closure, Hainan has added 4,396 new foreign trade registered enterprises, with many companies signing contracts and increasing investments, showing optimism for the new year [22] - A business leader mentioned that they have imported over 5 million yuan worth of "zero tariff" biomedical technology equipment, saving nearly 1 million yuan, and expect to establish a project worth over 20 million yuan by 2026 [24] - Another business leader projected a 20% increase in orders for 2026 compared to 2025, indicating growth expectations [25]

Core Viewpoint - Haier Biomedical has received a report from Qindao Jiushi Investment Management Co., indicating that Jiushi Youxuan No. 1 Fund plans to increase its stake in the company by 15,897,909 shares, representing 5.00% of the total share capital, due to a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [1][2]. Group 1 - Jiushi Youxuan No. 1 Fund is currently the second-largest circulating shareholder of Yinkang Life, showcasing its strategic focus on the medical technology sector and recognition of Haier Biomedical's solid fundamentals and clear growth logic [2]. - Haier Biomedical, a leader in low-temperature storage equipment in the biomedical sector, achieved a net profit of 143 million yuan in the first half of 2025, with new industry revenue accounting for 47% of total revenue, driving performance growth [2]. - The company has established a collaborative development framework across four major industries: low-temperature storage, smart medication, blood technology, and laboratory solutions, with significant market shares in various segments [2]. Group 2 - Haier Group, the actual controller of Haier Biomedical, has recently formed a comprehensive strategic partnership with Ant Group to promote the digital upgrade of healthcare services, positioning Haier Biomedical for new growth opportunities [3]. - The investment from Jiushi Youxuan No. 1 Fund is seen as a recognition of Haier Biomedical's technological barriers and growth potential, which may boost investor confidence and provide stronger momentum for the company's long-term development [3].

Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - The company, Qingdao Haier Biomedical Co., Ltd., is set to hold a half-year performance briefing on August 28, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in a Q&A session [2][3]. Group 1: Meeting Details - The performance briefing will take place on August 28, 2025, from 13:00 to 14:00 [5]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from August 21 to August 27, 2025, through the Roadshow Center website or via the company's email [6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with investors [3][6]. - Contact information for the company's securities department is provided for further inquiries [6].

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 50.00 per share to RMB 49.5367 per share following the implementation of the 2024 annual profit distribution plan [1][2][3] Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its shares using its own funds through the Shanghai Stock Exchange, with a total repurchase amount between RMB 100 million and RMB 200 million within 12 months from the board's approval date [1] 2. Reasons for Adjusting the Maximum Repurchase Price - The adjustment is due to the company's decision to distribute a cash dividend of RMB 4.7 per 10 shares to all shareholders, which affects the base for calculating the repurchase price [2][3] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend per share) / (1 + change in circulating shares ratio). The cash dividend per share is approximately RMB 0.4633 based on the total shares participating in the distribution [3] 4. Estimated Repurchase Quantity - With the adjusted maximum repurchase price of RMB 49.5367, the company estimates it can repurchase approximately 4.0374 million shares, representing about 1.27% of the total share capital, based on the upper limit of RMB 200 million [4] 5. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations while making repurchase decisions based on market conditions [5]